Alzheimer Disease study: HMSC
Official title Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
ClinicalTrials.gov ID: NCT06781333
What this study is testing
What is hMSC?
An investigational intravenous infusion of mesenchymal stem cells being studied for behavioral problems in moderate to severe Alzheimer’s disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see whether adding one infusion of mesenchymal stem cells to usual antipsychotic treatment can reduce behavioral problems in Alzheimer’s patients.
- Who it's for
- Adults diagnosed with moderate to severe Alzheimer’s disease who experience agitation.
- What's involved
- Participants will receive one infusion of mesenchymal stem cells while continuing their current antipsychotic medication. They will have follow‑up visits and assessments to monitor changes in behavior.
- Time commitment
- The study lasts several months, with scheduled visits for the infusion and subsequent follow‑up appointments to track progress.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 90
You may be able to join if
- Adults 55-90 years at the time of signing consent
- A diagnosis of probable Alzheimer disease (AD), defined by the National Institute of Neurological and Communicative Disorders and Stroke and the...
- Previous computed tomography or magnetic resonance imaging scan of the brain with findings consistent with a diagnosis of Alzheimer disease
- A diagnosis of behavioral symptoms that include any of the following: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety...
- Onset of behavioral symptoms at least 4 weeks prior to screening.
You likely can't join if
- Dementia other than AD
- Patient with severe depression. Patient with controlled depression is allowed to participate.
- Recent history of substance abuse
- History of bleeding disorders, HIV, Hepatitis C Virus or Hepatitis B Virus
- Recent history (within 3 years) of malignancies, except for treated basal cell, squamous carcinoma or melanoma in situ, prostate in situ, cervical...
- Uncontrolled medical conditions (hypertension, diabetes, unstable angina or Myocardial Infarction within 1 year prior to screening)
See the full eligibility criteria
- Adults 55-90 years at the time of signing consent
- A diagnosis of probable Alzheimer disease (AD), defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)...
- Previous computed tomography or magnetic resonance imaging scan of the brain with findings consistent with a diagnosis of Alzheimer disease
- A diagnosis of behavioral symptoms that include any of the following: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition...
- Onset of behavioral symptoms at least 4 weeks prior to screening.
- Treatment with antipsychotic medication for at least 4 weeks prior to the hMSC infusion.
- Patients unable to consent should have a Legally Authorized Representative or Proxy to provide consent on their behalf.
- Have a family member or friend (study partner) who has frequent and sufficient contact with the patient and able to answer questions about the participant's behavior.
- Dementia other than AD
- Patient with severe depression. Patient with controlled depression is allowed to participate.
- Recent history of substance abuse
- History of bleeding disorders, HIV, Hepatitis C Virus or Hepatitis B Virus
- Recent history (within 3 years) of malignancies, except for treated basal cell, squamous carcinoma or melanoma in situ, prostate in situ, cervical carcinoma in situ.
- Uncontrolled medical conditions (hypertension, diabetes, unstable angina or Myocardial Infarction within 1 year prior to screening)
- History of bleeding disorder
- Currently receiving (or received within four weeks of screening) experimental agents for the treatment of Alzheimer's Disease or enrolled in clinical trials in the prior 3 months.
- Be a transplant recipient or in any other active medical condition than in the opinion of the investigator may compromise the safety or compliance of the patient or preclude successful completion of the study
- Be premenopausal
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.